To date, no FDA safety communication has identified colorectal cancer as a safety signal for GLP-1 receptor agonists
WHO, 2010) Systemic signs include Hemostatic abnormalities (e.g., spontaneous bleeding, incoagulable blood), Cardiovascular complications (e.g., hypotension, shock, arrhythmia, abnormal electrocardiogram), Evidence of rhabdomyolysis or hemolysis (e.g., black urine)
Combined with the direct GLP-1 pathway effects, total systolic reductions often reach 1015 mmHg or more in people with baseline hypertension
If growth hormone optimization is the target, CJC-1295/Ipamorelin is often sufficient without layering additional compounds
That's a real gap